AIM ImmunoTech Inc. (AIM) Stock

AIM ImmunoTech Inc. (AIM) is a Healthcare stock trading at $0.26 (as of 2026-08-21), with a market capitalization of $3.81M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

AIM ImmunoTech Inc. is engaged in research and development of therapeutics aimed at conditions including cancers, viral diseases, and immune-deficiency disorders. Its product portfolio includes Ampligen (rintatolimod) and Alferon N Injection (interferon alfa), with additional development efforts across multiple cancer types and viral and immune-related conditions in the United States.

Understand AIM ImmunoTech Inc.: how it makes money

AIM ImmunoTech develops immuno-therapy drugs for cancers, viral diseases, and immune-deficiency disorders, with flagship products Ampligen and Alferon N Injection that are commercialized and supported by ongoing research and development.

Because AIM ImmunoTech is an R&D-based immuno-pharma company, its long-term economics depend on turning clinical and product development progress into usable, commercial therapeutics across specific treatment indications.

Business quality (Weak): No reportable segments or operational KPI labels were provided, so investors have limited company-specific operating metrics to track from the given data.

Bull case

  • Flagship immuno-therapeutics with defined clinical uses: Ampligen (rintatolimod) is described as being developed to treat chronic fatigue syndrome, and Alferon N Injection (Interferon alfa) is described for the treatment of genital warts.
  • Ongoing development adds potential indication breadth: The company is also developing Ampligen for additional potential treatment areas beyond its flagship use.

Bear case

  • Profitability pressure in the most recent period provided: For the period ending 2026-03-31, the provided operating margin is -10118.2 (deeply negative).
  • Execution risk typical of therapeutics development: The business is centered on R&D of therapeutics for multiple serious disease areas, which introduces uncertainty around development progress and successful treatment delivery.
Valuation — source: SEC EDGAR (first-party)
Price$0.26
Market Cap$3.81M
Price / Book0.49
Price / Sales39.69
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$88000.00
Net Margin-15861.4%
Revenue Growth (YoY)-48.2%
EPS Growth (YoY)2680.6%
Financial Health — source: SEC EDGAR
Altman Z-Score-113.90 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVirtu Financial LLC ($30000.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOThomas K. Equels
Employees21
CountryUS
IPO Date1995-11-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Intensity Therapeutics, Inc. (INTS)
  • Passage Bio, Inc. (PASG)
  • IN8bio, Inc. (INAB)
  • Senti Biosciences, Inc. (SNTI)
  • Creative Medical Technology Holdings, Inc. (CELZ)
  • VivoSim Labs, Inc. (VIVS)
  • Calidi Biotherapeutics, Inc. (CLDI)
  • Ernexa Therapeutics Inc. (ERNA)
AIM earnings history · AIM institutional & insider holders · AIM KPIs & operating metrics · AIM financials · AIM investor presentations & press releases · AIM SEC filings · AIM peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.